Agitation in Alzheimer's Disease Treatment
May 11, 2026
Agitation in Alzheimer’s Disease Treatment Landscape: A New Dawn With AUVELITY’s Breakthrough Approval
Summary In the United States alone, agitation in Alzheimer’s disease represented nearly 5 million diagnosed cases, highlighting a considerable yet often underappreciated burden among patients. Brexpiprazole (REXULTI) marked a key milestone as the first FDA-approved therapy specifically indicated for agitatio...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
